Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Novartis AG | 958 |
| 2 | Janssen Pharmaceutica NV | 345 |
| 3 | Bayer Pharma AG | 329 |
| 4 | Takeda Pharmaceutical Co Ltd | 205 |
| 5 | F Hoffmann La Roche AG | 182 |
| 6 | Pharmacia and Upjohn Co | 180 |
| 7 | Cartesian Therapeutics Inc | 136 |
| 8 | Kymera Therapeutics Inc | 124 |
| 9 | Sterix Ltd | 122 |
| 10 | Amgen Inc | 112 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,408 |
| 2 | A61K | Medicinal preparations | 10,657 |
| 3 | C07D | Heterocyclic compounds | 4,630 |
| 4 | C07J | 2,812 | |
| 5 | G01N | Investigating / analysing materials | 2,278 |
| 6 | C12N | Microorganisms, enzymes | 1,703 |
| 7 | C07K | Peptides | 1,468 |
| 8 | C12P | Fermentation, enzyme processes | 1,047 |
| 9 | C12Q | Measuring/testing involving enzymes | 987 |
| 10 | C07C | Acyclic and carbocyclic compounds | 913 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| SELECTIVE MICROBIOLOGICAL PREPARATION OF ANDROST-4-ENE-3,17-DIONE | 1973 | GD Searle LLC | 73 |
| 6-substituted androsta-1,4-diene-3,17-diones | 1989 | Pfizer Italia SRL | 71 |
| Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis | 1980 | BRODIE, ANGELA M | 56 |
| Substituted androsta-1,4-diene-3,17-diones | 1990 | Pfizer Italia SRL | 37 |
| Androst-4-ene-3,17-diones and process for their preparation | 1989 | Pfizer Italia SRL | 25 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Hormonal and reproductive studies | 40 |
| 2 | Ovarian function and disorders | 27 |
| 3 | Estrogen and related hormone effects | 22 |
| 4 | Sexual Differentiation and Disorders | 10 |
| 5 | Reproductive Physiology in Livestock | 8 |
| 6 | Reproductive Biology and Fertility | 7 |
| 7 | Hormonal Regulation and Hypertension | 5 |
| 8 | Cancer Risks and Factors | 4 |
| 9 | Sexual function and dysfunction studies | 4 |
| 10 | Sperm and Testicular Function | 4 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Frank Z. Stanczyk | University of Southern California | 60 |
| 2 | Mitch Dowsett | Royal Marsden Hospital | 57 |
| 3 | Fernand Labrie | Université Laval | 56 |
| 4 | Christopher Longcope | University of Massachusetts Chan Medical School | 30 |
| 5 | Jan-Ακε Gustafsson | Karolinska Institutet | 29 |
| 6 | R. J. Scaramuzzi | Commonwealth Scientific and Industrial Research Organisation | 28 |
| 7 | Angela Brodie | University of Maryland, Baltimore | 26 |
| 8 | L Stárka | Institute of Endocrinology | 26 |
| 9 | Mitsuteru Numazawa | Tohoku Medical and Pharmaceutical University | 25 |
| 10 | L. J. Spicer | Oklahoma State University | 22 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer | 2006 | 1076 | Prostate Cancer Treatment and Research |
| Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. | 2002 | 1041 | Ovarian function and disorders |
| Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. | 1986 | 994 | Sperm and Testicular Function |
| Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy | 2005 | 991 | Ovarian function and disorders |
| Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease* | 1980 | 918 | Ovarian function and disorders |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Andro?
Which organizations hold the most patents related to Andro?
What research topics are most prominent in the scientific literature on Andro?
What are the most-cited publications about Andro and its biological roles?
How has research and patenting activity on Andro changed in recent years?